Cancer Research The Future of Cancer Research: Science and Patient Impact Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhou, S.
Right arrow Articles by Wallace, K. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, S.
Right arrow Articles by Wallace, K. B.
[Cancer Research 61, 771-777, January 15, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

Cumulative and Irreversible Cardiac Mitochondrial Dysfunction Induced by Doxorubicin1

Shaoyu Zhou, Anatoli Starkov, M. Kent Froberg, Richard L. Leino and Kendall B. Wallace2

Department of Biochemistry and Molecular Biology, Toxicology Graduate Program, University of Minnesota School of Medicine, Duluth, Minnesota 55812


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Interference with mitochondrial calcium regulation is proposed to be a primary causative event in the mechanism of doxorubicin-induced cardiotoxicity. We previously reported disruption of mitochondrial calcium homeostasis after chronic doxorubicin administration (Solen et al. Toxicol. Appl. Pharmacol., 129:214–222, 1994). The present study was designed to characterize the dose-dependent and cumulative interference with mitochondrial calcium regulation and to assess the reversibility of this functional lesion. Sprague Dawley rats were treated with 2 mg/kg/week doxorubicin s.c. for 4–8 weeks. With succinate as substrate, cardiac mitochondria isolated from rats after 4 weeks of treatment with doxorubicin expressed a lower calcium loading capacity compared with control. This suppression of calcium loading capacity increased with successive doses to 8 weeks of treatment (P < 0.05) and persisted for 5 weeks after the last doxorubicin injection, and was corroborated by dose-dependent and irreversible histopathological changes. Preincubation of mitochondria with tamoxifen, DTT, or monobromobimane did not reverse the diminished calcium loading capacity caused by doxorubicin. In contrast, incubation with cyclosporin A abolished any discernible difference in mitochondrial calcium loading capacity between doxorubicin-treated and saline-treated rats. The decrease in cardiac mitochondrial calcium loading capacity was not attributable to bioenergetic changes in the electron transport chain, because the mitochondrial coupling efficiency was not altered by doxorubicin treatment. However, the ADP/ATP translocase content was significantly lower in mitochondria from rats that received 8 weeks of doxorubicin treatment. These data indicate that doxorubicin treatment in vivo causes a dose-dependent and irreversible decrease in mitochondrial calcium loading capacity. Suppression of adenine nucleotide translocase content may be a key factor altering the calcium-dependent regulation of the mitochondrial permeability transition pore, which may account for the cumulative and irreversible loss of myocardial function in patients receiving doxorubicin chemotherapy.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
DOX,3 an anthracycline drug widely used for the treatment of various cancers, causes a cumulative dose-dependent cardiac toxicity that is characterized by an irreversible dilated cardiomyopathy and congestive heart failure (1 , 2) . Although several mechanisms have been suggested to explain this cardiotoxicity, the exact mechanism and its metabolic consequences remain unclear. Biochemical and physiological data favor the hypothesis that DOX causes the formation of free radicals that stimulate lipid peroxidation and alter cellular membrane integrity (3, 4, 5, 6, 7) . Accordingly, a number of efforts have been made to use exogenously supplemented antioxidants to protect the heart from DOX-induced damage (8 , 9) . However, the effectiveness is varied and limited. Alternatively, transgenic mice that overexpress methallothionein are resistant to DOX-induced morphological changes in the myocardium and creatine kinase release from the heart (10) . Yet, the protection of methallothionein on DOX cardiotoxicity is still controversial (11) . Additional studies are needed to delineate the exact mechanism of DOX-induced oxidative damage, particularly to explore the clinical potential of antioxidants in protecting against DOX cardiotoxicity.

Induction of the MPT by oxidants has been proposed to play an important role in chemical-induced tissue injury and cell killing both in vitro and in vivo (12, 13, 14, 15, 16, 17) . This leads to the implication of oxidative alteration of mitochondrial calcium transport as the mechanism of toxicity. DOX and its aglycone metabolite alter mitochondrial calcium retention and diminish the capacity of isolated mitochondria to accumulate calcium in vitro (18, 19, 20) as well as in vivo (21 , 22) . This DOX-induced interference with mitochondrial calcium regulation is a consequence of selective activation of the CsA-sensitive calcium release channel (20 , 23) . A relationship has been suggested between the induction of mitochondrial calcium cycling and DOX cardiotoxicity. Ruthenium red, an inhibitor of mitochondrial calcium uptake, and CsA protect cardiac myocytes from DOX-induced cell killing (22 , 24) . This is also supported by the observation of in vivo prevention of DOX cardiotoxicity by CsA or FK506 (25) .

We recently demonstrated that activation of the selective CsA-sensitive calcium channel of cardiac mitochondria by DOX in vitro (23) is also manifested in cardiac mitochondria isolated from rats after chronic in vivo treatment with DOX (21) . Furthermore, we have characterized the cumulative dose-dependent interference with mitochondrial calcium transport by DOX and found that this is manifested as an increased sensitivity to calcium-induced injury in cardiac myocytes isolated from rats exposed in vivo (22) . These data suggest that interference with cardiac mitochondrial calcium homeostasis may be a critical factor underlying the DOX-induced cardiotoxicity and may be responsible for the clinical manifestations of cardiomyopathy. Because the DOX-induced cardiomyopathy is irreversible, we question whether the disruption of mitochondrial calcium regulation can be restored after discontinuation of DOX administration. In this study, we assessed the dose-dependence and reversibility of the decreased mitochondrial calcium loading capacity and explored the potential mechanisms underlying this important pathogenic process.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Chemicals.
D-mannitol was purchased from Aldrich Chemical Co. (Milwaukee, WI) and ultra-pure sucrose from Schwarz/Mann Biotech (Cleveland, OH). DOX was purchased from Pharmacia & Upjohn Co. (Kalamazoo, MI). CsA was a generous gift from Sandoz Pharmaceuticals (East Hanover, NJ). cATR was a gift from Dr. A. Starkov (Moscow State University). All of the other chemicals were of the highest grade available from Sigma Chemical Co. (St. Louis, MO).

Animals.
Male Sprague Dawley rats (Harlan Labs, Madison, WI) were maintained in AAALAC-accredited, climate-controlled facilities and allowed free access to food (Purina Chow) and water. Rats received 4–8 weekly s.c. injections of either DOX (2 mg/kg) or an equivalent volume of saline (1 ml/kg). The animals were killed by decapitation 1, 3, or 5 weeks after the last injection and the heart immediately excised to cold buffer.

Isolation of Cardiac Mitochondria.
Cardiac mitochondria were isolated by differential centrifugation after homogenization and proteolytic digestion as described previously (23) . The final mitochondrial pellet was suspended in 100 µl of medium containing 225 mM mannitol, 75 mM sucrose, and 10 mM MOPS (pH 7.4). Mitochondrial protein concentration was estimated by the Bradford method using BSA as the protein standard (26) .

{Delta}{Psi}.
{Delta}{Psi} was estimated using an ion-selective electrode to measure the distribution of the tetraphenylphosphonium ion (TPP+) according to previously established methods (27) . The reference electrode was AgCl. Mitochondria (0.25 mg/ml) were suspended with constant stirring at room temperature in 200 mM sucrose-10 mM Tris-MOPS (pH 7.2)-10 mM KH2PO4 supplemented with 1 µM rotenone and 1 µg/ml oligomycin. TPP+ was added to a final concentration 1.6 µM and the mitochondria energized by adding succinate to a final concentration of 5 mM.

Mitochondrial Swelling.
Mitochondrial swelling was recorded as a decrease in light absorbance at 560 nm (Beckman DU 7400 spectrophotometer equipped with a magnetic stirrer assembly). Mitochondria were suspended at 0.25 mg protein/ml in 200 mM sucrose-10 mM Tris-MOPS (pH 7.2)- 10 mM KH2PO4 supplemented with 1 µM rotenone and 1 µg/ml oligomycin; 260 µM Ca2+ was added before the mitochondria. The reaction was started with the addition of 5 mM succinate. Where indicated in the figures, 1 µM CsA was added before Ca2+ .

Mitochondrial Calcium Loading Capacity.
Mitochondrial calcium loading capacity is a measure of the total amount of Ca2+ that mitochondria are capable of accumulating from the incubation medium before undergoing the MPT and releasing it back to the medium. The process is a measure of calcium-induced calcium release, which may be synonymous with induction of the Ca2+-dependent MPT. It was estimated by using a calcium-selective electrode made of commercial calcium-ionophore membrane from Fluke Chemical Corp. (Milwaukee, WI) and a AgCl reference electrode. The calcium electrode was calibrated by sequential additions of CaCl2 solution: 20 µM, 20 µM, 40 µM, 80 µM, and 100 µM (total 260 µM). The calcium loading capacity is expressed as nmoles of Ca2+ per mg of mitochondrial protein.

Light and Electron Microscopy.
Small blocks of cardiac muscle from the mid-portion of the lateral wall of the left ventricle were fixed in 2.5% glutaraldehyde-2% formaldehyde in 0.1 M phosphate buffer (pH 7.4), postfixed in 1% OsO4 in the same buffer, dehydrated in graded acetone solutions, and embedded in epon-araldite. One-µm thick sections for light microscopy were stained at 55°C with 0.25% toluidine blue in 1% sodium borate after treatment with 0.l N HCl (28) and 1% ruthenium red (29) . Thin sections for electron microscopy were stained with lead citrate and uranyl acetate.

Cytochrome Content.
Mitochondrial cytochrome content was determined spectrophotometrically as described previously (30 , 31) . Two mg of isolated heart mitochondria were dissolved in 2 ml of 2% Triton X-100 in 0.1 M phosphate buffer (pH 7.0). To each of two cuvettes (one served as a sample with the other as a reference), was added 1 ml of the Triton X-100-solubilized mitochondrial suspension. A few grains of sodium hydrosulfite were added to the sample cuvette and mixed by repeated inversion until the sodium hydrosulfite was dissolved. The differences in absorbance at the following pairs of wavelengths were then measured: 550–535 (cytochrome c), 554–540 (cytochrome c1), 563–577 (cytochrome b), and 605–630 nm (cytochrome a). The calculation of cytochrome content was based on the millimolar extinction coefficient for the respective cytochromes as reported by Williams (30) .

Mitochondrial Respiration.
Mitochondria were incubated at a concentration of 0.25 mg/ml in 1 ml of 200 mM sucrose-10 mM Tris-MOPS (pH 7.2)-10 mM KH2PO4 supplemented with 5 mM glucose and 20 units of hexokinase. The incubations were performed at 30°C in a closed and magnetically stirred reaction chamber equipped with a Clark-type electrode. The reactions were started by adding 5 mM glutamate plus malate. State 3 respiration was initiated by adding 50 µM ADP. After static state 3 respiration was obtained (about 2 min), cATR was then added. A titration curve was obtained by stepwise addition of cATR to respiring isolated mitochondria. Plots of O2 consumption versus cATR appeared biphasic, with an increasing inhibitory segment followed by a steady respiration indicating that state 3 respiration was completely inhibited. The amount of cATR corresponding to complete inhibition of state 3 respiration was used to estimate ANT content assuming a 1:1 binding stoichiometry, which was expressed as cATR content per mg mitochondrial protein.

Statistical Data Analysis.
All of the data were expressed as the mean ± SE of three to five independent experiments. The data were analyzed using one-way ANOVA, and differences among individual means were compared using the Bonferroni/Dunn test. A probability of P < 0.05 was used as the criterion for statistical significance.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Mitochondrial Calcium Loading Capacity.
Mitochondria possess a finite capacity for accumulating calcium before undergoing the calcium-dependent MPT. In this study we define mitochondrial calcium loading capacity as the total amount of Ca2+ that mitochondria are able to accumulate before they start releasing it back to the incubation medium. This is an important parameter to characterize mitochondrial integrity and indicates the resistance of mitochondria to induction of the Ca2+-dependent MPT. As shown in Fig. 1Citation , the Ca2+ electrode was calibrated by sequential additions of CaCl2 solution. Succinate-supported mitochondria started to take up Ca2+ to a point (downward deflection in the trace), then released Ca2+ back into the medium (upward deflection, Fig. 1, cCitation ). This Ca2+-induced mitochondrial Ca2+ release indicated the opening of the MPT pore, which was confirmed by adding CsA (Fig. 1Citation , trace d), a specific inhibitor of the mitochondrial pore (32) , to block the Ca2+ release. In the presence of CsA, mitochondria accumulated and retained all of the added Ca2+ (Fig. 1, d)Citation . Associated with this Ca2+-induced mitochondrial Ca2+ release was a depolarization of the {Delta}{Psi} (Fig. 1, aCitation , upward deflection), which was prevented by CsA (Fig. 1, b)Citation . Induction of the MPT by loading with Ca2+ was further evidenced by the fact that adding CsA prevented the calcium-induced mitochondrial swelling (Fig. 2)Citation . It should be noted that the prevention of calcium-induced mitochondrial swelling by CsA was not complete, as it was for {Delta}{Psi}. This is because of different experimental conditions. Unlike the {Delta}{Psi} experiment conducted in an open chamber, mitochondrial swelling was performed in a small cuvette in which oxygen diffusion was limited. Under these conditions, O2 consumption by Ca2+-uncoupled mitochondria leads to relative hypoxia, which causes mitochondrial swelling independent of CsA-sensitive MPT (33) .



View larger version (16K):
[in this window]
[in a new window]
  		Fig. 1. A representative protocol for estimating mitochondrial calcium loading capacity. Mitochondrial calcium (traces c and d) and membrane potential (traces a and b) were recorded simultaneously in an open glass chamber equipped with a Ca2+-selective electrode and a TPP+ electrode, respectively. To 1 ml of incubation medium containing 200 mM sucrose-10 mM Tris-MOPS (pH 7.2)-10 mM KH2PO4, was added 1.6 µM TPP+, 0.25 mg mitochondria, 1 µM rotenone, and 1 µg/ml oligomycin. Once a steady-state membrane potential was established, sequential additions of Ca2+ were made to calibrate the Ca2+ electrode (20 µM, 20 µM, 40 µM, 80 µM, and 100 µM, total 260 µM). The reaction was started by adding 5 mM succinate. Calcium capacity was estimated as the maximum amount of Ca2+ accumulated by mitochondria before releasing Ca2+ back into the medium. Where indicated (traces b and d), 1 µM CsA was added before mitochondria.

 


View larger version (11K):
[in this window]
[in a new window]
  		Fig. 2. Inhibitory effect of CsA on calcium-induced mitochondrial swelling. Mitochondria (0.25 mg) were suspended in 1 ml of medium containing 200 mM sucrose, 10 mM Tris-MOPS (pH 7.2), 10 mM KH2PO4, 1 µM rotenone, and 1 µg/ml oligomycin. Ca2+ (260 µM) was added before mitochondria. Absorbance at 560 nm was recorded for 4 min before adding succinate to start the reaction. Where indicated, CsA (1 µM) was added before mitochondria.

 
Irreversible Mitochondrial Dysfunction.
Mitochondria isolated from rat hearts receiving 4 weeks of treatment with DOX expressed a slightly lower calcium loading capacity compared with control (Fig. 3)Citation . The decrease in mitochondrial calcium loading capacity was most evident after 8 weeks of treatment (P < 0.05). The diminished capacity to accumulate Ca2+ did not reverse over 3–5 weeks after discontinuation of DOX administration, which is consistent with the clinically observed irreversible cardiomyopathy.



View larger version (20K):
[in this window]
[in a new window]
  		Fig. 3. Calcium loading capacity of cardiac mitochondria from rats receiving 4–8 weekly injections of DOX/saline. Calcium loading capacity was estimated as described in Fig. 1Citation . 4+1w, 6+1w, and 8+1w represent mitochondria isolated 1 week after the last of 4, 6, or 8 weeks treatment, respectively. 8+3w and 8+5w represent mitochondria isolated 3 or 5 weeks after the last of 8 weekly injections. Data are expressed as the mean ± SE of three separate mitochondrial preparations. *, a statistically significant difference compared with saline control (P < 0.05).

 
Histopathological Examination.
When examined by light and electron microscopy, cardiac myocytes of saline-injected rats had normal morphology (Table 1Citation ; Figs. 4ACitation and 5ACitation ). Incipient pathology occurred in most cardiac myocytes of rats receiving 6 weeks of DOX injections (Figs. 4BCitation and 5B)Citation . The most common ultrastructural change was a slight enlargement of the T-tubules that was often accompanied by distension of the sarcoplasmic reticulum (Fig. 4B)Citation . After 8 weeks of treatment with DOX, frank ultrastructural pathology was apparent, including cytoplasmic vacuolation, mitochondrial and myofibrillar damage and loss, and cellular edema. Ultrastructural injury was not repaired at 3 and 5 weeks after cessation of DOX treatment and became even more extensive (Fig. 4, C and D)Citation , which was correlated with the persistent decrease in mitochondrial calcium loading capacity. Worsening pathology with length of DOX administration was also evident at the light microscopic level (Fig. 5, B, C>, and D)Citation , with increasing duration of treatment causing increased degrees of cytoplasmic vacuolization and frank degeneration.


View this table:
[in this window]
[in a new window]
  		Table 1 Histopathological grading of DOX-induced cardiomyopathy

 


View larger version (179K):
[in this window]
[in a new window]
  		Fig. 4. Representative electron micrographs of cardiac myocyte sections comparing control and DOX treatments. A, control myocytes show normal morphology; B, myocyte (DOX 6+1w treatment) showing enlarged T-tubules accompanied by distension of the sarcoplasmic reticulum and disarray and loss of mitochondria; C, myocyte (DOX 8+5w treatment) showing vacuolation, mitochondrial degeneration (m), and myofibrillar disarray; D, portions of myocytes (DOX 8+5w treatment) with various degrees of damage. Arrowheads, the most severely damaged myocyte is edematous and shows a near absence of subsarcolemmal mitochondria. Note that the DOX-treated myocytes are hypercontracted. Scale bar: A, 1 µM for A, B, C; D, 4.2 µm.

 


View larger version (154K):
[in this window]
[in a new window]
  		Fig. 5. Representative light micrographs of cardiac myocytes (x400; toluidine blue and ruthenium red) comparing control and DOX treatments. A, control myocytes show normal morphology; B, myocytes (DOX 6+1w treatment) with small cytoplasmic vacuoles are present within a minority of cardiac myocytes; C, myocyte damage (DOX 8+1w treatment) is present in ~20% of myocytes with more extensive cytoplasmic vacuolization; D, severe myocyte degeneration (DOX 8+5w treatment) is present in greater than 30% of myocytes.

 
Effect of DOX Treatment on the Bioenergetics of Mitochondria.
It is well established that the MPT is strongly influenced by the transmembrane potential (34) . Previous studies demonstrated that DOX suppresses the expression of COXII of COX (35) , which is a pivotal enzyme in the mitochondrial electron transport chain. Therefore, the mitochondrial content of cytochromes a, b, c, and c1 was determined as an indication of the efficiency of the electron transport chain. However, no differences were found in the content of any cytochrome between cardiac mitochondria from DOX-treated and saline-treated animals (Fig. 6)Citation . There is still a possibility that DOX treatment may depress the activity of COX by means other than modulating gene expression. Instead of estimating the activity of COX, mitochondrial coupling efficiency was compared by titrating {Delta}{Psi} with FCCP. Mitochondrial coupling efficiency is indicative of respiratory chain efficiency and may directly influence mitochondrial calcium loading capacity. As illustrated in Fig. 7Citation , DOX treatment did not significantly alter the relationship between FCCP concentration and {Delta}{Psi}, which indicated that alteration of mitochondrial bioenergetics is not a critical factor causing the decrease in mitochondrial calcium loading capacity by DOX.



View larger version (30K):
[in this window]
[in a new window]
  		Fig. 6. Cytochrome content of mitochondria from rats receiving 4–8 weekly injections of DOX/saline. 4+1w, 6+1w, 8+1w, 8+3w, and 8+5w are defined as in Fig. 3Citation . Cytochrome content was measured as described in "Materials and Methods." Data are expressed as the mean ± SE of 3 mitochondrial preparations. A, cytochrome a (cyt a) content; B, cytochrome b (cyt b) content; C, cytochrome c (cyt c) content; D, cytochrome c1 (cyt c1) content.

 


View larger version (12K):
[in this window]
[in a new window]
  		Fig. 7. Effect of FCCP on membrane potential of heart mitochondria isolated from rats killed 1 week after receiving 8 weekly injections of DOX/saline. The incubation medium contained 200 mM sucrose, 10 mM Tris-MOPS (pH 7.2), 5 mM succinate, 10 mM KH2PO4, 1 µM rotenone, 1 µg/ml oligomycin, and 0.2 mM EGTA. The experiments were started by adding 0.25 mg mitochondria to 1 ml of the incubation medium. Once the steady-state membrane potential was reached, FCCP was added sequentially (10 nM each addition). Membrane potential was recorded once a steady state was achieved at each of the indicated concentrations of FCCP. Data represent percentage of the initial membrane potential and are expressed as the mean ± SE of three separate mitochondrial preparations.

 
Effect of CsA and Antioxidants on Mitochondrial Calcium Loading Capacity.
Considering the hypothesis of the oxidative alteration of mitochondria by DOX treatment, it might be possible to reverse the decreased mitochondrial calcium loading capacity by adding selected antioxidants. Previous studies have reported that TAM, DTT, and mBrB inhibit the induction of the MPT by Ca2+ in vitro (20 , 33 , 36 , 37) . Cardiac mitochondria from DOX-treated rats preincubated with TAM, however, exhibited only a marginal increase in calcium loading capacity (P > 0.05), whereas mBrB (data not shown) and DTT did not show any protection compared with control (Fig. 8)Citation . Interestingly, in the presence of CsA, mitochondria from DOX-treated animals displayed a >2-fold increase in calcium loading capacity, which was not different from saline control in the presence of CsA. This indicates that the reversible oxidative alteration of mitochondrial proteins is not a major factor responsible for the decrease in mitochondrial calcium loading capacity caused by DOX.



View larger version (37K):
[in this window]
[in a new window]
  		Fig. 8. Effect of CsA, TAM, and DTT on mitochondrial calcium loading capacity. Saline and DOX represent cardiac mitochondria isolated from rats receiving 8 weekly injections of saline or DOX, respectively. Calcium loading capacity was measured as described in Fig. 1Citation . TAM (10 nmol/0.25 mg protein), DTT (100 mM), and CsA (1 µM) were added 1 min prior to calibration with Ca2+. Data are expressed as the mean ± SE of 3–6 mitochondrial preparations. a and b, statistically significant differences compared with saline and DOX controls, respectively (P < 0.05).

 
Diminished ANT Content Caused by DOX Treatment.
Jeyaseelan et al. (38) have shown that the ADP/ATP translocase gene is down-regulated in cultured cardiac myocytes exposed to DOX. In the present study, we examined whether the content of this ANT was changed in cardiac mitochondria isolated from rats after chronic in vivo treatment with DOX. cATR reacts with ANT in a 1:1 stoichiometry (39 , 40) . Accordingly, the ANT content in mitochondria can be estimated by titrating the active-state respiration with cATR as illustrated in Fig. 9ACitation . It was found that ANT content was significantly diminished in cardiac mitochondria from DOX-treated animals compared with control (Fig. 9B)Citation . The ANT contents in treated and control animals were 1885 ± 86 and 1585 ± 31 (pmol cATR/mg mitochondrial protein), respectively. This 15% decrease in ANT content correlates with the decreased mitochondrial calcium loading capacity. Because ADP/ATP translocase is a principal component of the MPT pore complex (41 , 42) , it is not surprising that the decrease in translocase content correlates with the increased sensitivity of mitochondria to calcium-induced pore opening.



View larger version (24K):
[in this window]
[in a new window]
  		Fig. 9. Determination of ANT content of mitochondria from rats receiving 8 weekly injections of DOX as determined by titrating with cATR. Mitochondrial respiration was recorded as described in "Materials and Methods." A, a representative pattern of titration curves shows the method of estimation of ANT content. B, ANT content of mitochondria is expressed as pmol cATR per mg mitochondrial protein. The values represent the mean ± SE of three mitochondrial preparations. *, a statistically significant difference compared with saline control (P < 0.05).

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Induction of the MPT is implicated in the mechanism of cell injury caused by many chemicals (12, 13, 14, 15, 16, 17) , including the pathogenesis of DOX-induced cardiotoxicity (21 , 23 , 24) . It has been proposed that DOX-induced free radical generation causes oxidative alteration of the MPT pore, which contributes to the development of DOX-induced cardiotoxicity. We recently reported that both cardiac mitochondria and cells isolated from DOX-treated animals express a dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cell death, both of which are prevented by adding CsA in vitro (22) .

In the present study, we further characterized the integrity of cardiac mitochondria isolated from animals exposed to DOX in vivo in terms of altering the mitochondrial calcium loading capacity. Mitochondria isolated from DOX-treated animals expressed a dose-dependent decrease in calcium loading capacity. The fact that this is blocked by CsA is indicative of an enhanced sensitivity to induction of the calcium-dependent MPT. Moreover, the decrease in calcium loading capacity did not reverse over a 5-week period after discontinuation of DOX treatment, which suggests that the alteration of mitochondrial calcium regulation is persistent and irreversible. This correlates with the fact that the elevated systolic myoplasmic calcium levels, which are not accompanied by an increase in inotropy, persist for up to 5 weeks after the last injection of DOX (43) .

It is known that mitochondria play a critical role in the regulation of cellular calcium concentration under pathological conditions. It has also been shown that mitochondria are involved in cellular calcium homeostasis under normal physiological conditions (44, 45, 46, 47) . Understanding the mitochondrial contribution to cytosolic calcium regulation may provide new clues to the mechanism of DOX-induced cardiac myocyte toxicity. A recent study by Miyamae et al. (48) demonstrates that mitochondrial calcium overload, not the cytosolic free calcium, is involved in reperfusion injury in intact beating hearts. Mitochondria with diminished calcium loading capacity, therefore, may be more susceptible to the high cytosolic calcium concentration induced by DOX as observed in the study by Kapelko et al. (43) . Indeed, in this study, we observed mitochondrial damage and loss, which is consistent with previous histopathological studies showing DOX-induced mitochondrial swelling, fusion, dissolution, and pronounced disorientation of the cristae (49, 50, 51) . Moreover, our histopathological studies showed that this mitochondrial damage was not repaired over 5 weeks after discontinuation of DOX treatment. All of this may be related to the persistent decrease in mitochondrial calcium loading capacity. Understanding of the mechanism(s) underlying the decrease in mitochondrial calcium loading capacity, therefore, is an important endeavor.

Treatment with DOX suppresses COX gene expression (51) . However, in the present study no difference was found in mitochondrial content of any of the cytochromes examined. Although the activity of COX was not estimated, the mitochondrial coupling efficiency was found to be similar between treated and control animals. Therefore, inhibition of mitochondrial bioenergetics does not appear to be responsible for the decrease in mitochondrial calcium loading capacity. TAM, DTT and mBrB, three antioxidants known to prevent induction of the MPT in vitro (20 , 33 , 36 , 37) did not reverse the sensitivity of cardiac mitochondria from DOX-treated rats to induction of the calcium-dependent permeability transition. This suggests that oxidative alteration of mitochondrial proteins is not a critical factor responsible for the decreased calcium loading capacity.

A number of studies have demonstrated that ADP/ATP translocase is involved in the MPT, although the exact mechanism is unclear (42 , 52 , 53) . Mitochondria from rat heart and liver vary in their ANT content (40 , 54) , which is proportional to their ability to accumulate calcium. In the present study, the content of this translocase was found to be less in cardiac mitochondria from DOX-treated rats compared with control. Moreover, the extent of decrease in this translocase content correlated with the decreased mitochondrial calcium loading capacity. Therefore, it may be that the decrease in ADP/ATP translocase content is responsible for the diminished mitochondrial calcium loading capacity after DOX treatment. Recently, Jeyaseelan et al. (38) reported that ADP/ATP translocase gene was down-regulated in cardiac myocytes exposed to DOX in culture. This suggests that the decrease in ANT content might be attributable to the altered regulation of gene expression caused by DOX. Considering the fact that the change in mitochondrial calcium loading capacity was irreversible, modulation in ANT gene regulation might be persistent as well. Interestingly, we recently found that mitochondrial DNA adducts persist for over 5 weeks after discontinuation of chronic DOX administration (55 , 56) . This dose-dependent and irreversible accumulation of DNA adducts correlates well with the cumulative and persistent histopathology and decrease in mitochondrial function.

In conclusion, we demonstrate that mitochondria from DOX-treated rats expressed a dose-dependent and irreversible decrease in calcium loading capacity that correlates with the accumulation of DNA adducts, histopathology, and clinically observed cardiomyopathy. We attribute the decrease in mitochondrial calcium loading capacity, in part, to the diminished ANT content and suggest that this altered regulation of mitochondrial calcium homeostasis may be a critical factor involved in the pathogenic pathway of the cumulative and irreversible cardiomyopathy associated with long-term DOX cancer chemotherapy.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by NIH Grant HL-58016. Back

2 To whom requests for reprints should be addressed, at Department of Biochemistry and Molecular Biology, University of Minnesota School of Medicine, Duluth, MN 55812. Phone: (218) 726-8899; Fax: (218) 726-8014. Back

3 The abbreviations used are: DOX, doxorubicin; MPT, mitochondrial permeability transition; CsA, cyclosporin A; cATR, carboxyatractyloside; {Delta}{Psi}, mitochondrial membrane potential; FCCP, carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone; TAM, tamoxifen; mBrB, monobromobimane; ANT, adenine nucleotide translocase; MOPS, 4-morpholinepropanesulfonic acid; COX, cytochrome c oxidase. Back

Received 3/13/00. Accepted 11/ 6/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin. Oncol., 19: 529-542, 1992.[Medline]
  2. Lefrak E. A., Pitha J., Rosenheim S., Gottlieb J. A. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer (Phila.), 32: 302-314, 1973.[Medline]
  3. Doroshow J. H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res., 43: 460-472, 1983.[Abstract/Free Full Text]
  4. Mimnaugh E. G., Trush M. A., Bhathagar M., Gran T. E. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug Adriamycin. Biochem. Pharmacol., 34: 847-856, 1985.[Medline]
  5. Olson R. D., Mushlin P. S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J., 4: 3076-3086, 1990.[Abstract]
  6. Powis G. Free radical formation by antitumor quinones. Free Radic. Biol. Med., 6: 63-101, 1989.[Medline]
  7. Singal P. K., Deally C. M. R., Weinberg L. E. Subcellular effects of Adriamycin in the heart: a concise review. J. Mol. Cell. Cardiol., 19: 817-828, 1987.[Medline]
  8. Myers C. E., Bonow R., Palmeri S., Jenkins J., Corden B., Locker G., Doroshow J., Epstein S. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcyteine. Semin. Oncol., 10: 53-55, 1983.[Medline]
  9. Unverferth D. V., Leier C. V., Balcerzak S. P., Hamlin R. L. Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in gods. Am. J. Cardiol., 56: 157-161, 1985.[Medline]
  10. Kang Y. J., Chen Y., Yu A., Voss-McCowan M., Epstein P. N. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J. Clin. Investig., 100: 1501-1506, 1997.[Medline]
  11. DiSilverstro R. A., Liu J., Klaassen C. D. Transgenic mice overexpressing metallothionein are not resistant to Adriamycin cardiotoxicity. Res. Commun. Mol. Pathol. Pharmacol., 93: 163-170, 1996.[Medline]
  12. Bernardi P. Mitochondria transport of cations: channels, exchangers, and permeability transition. Physiol. Rev., 79: 1127-1155, 1999.[Abstract/Free Full Text]
  13. Bernardi P., Broekemeier K. M., Pfeiffer D. R. Recent progress on regulation of the mitochondrial permeability transition pore, a cyclosporin-sensitive pore in the inner mitochondrial membrane. J. Bioenerg. Biomembr., 26: 509-517, 1994.[Medline]
  14. Gunter T. E., Pfeiffer D. R. Mechanisms by which mitochondria transport calcium. Am. J. Physiol, 258: C755-C786, 1990.[Abstract/Free Full Text]
  15. Gunter T. E., Gunter K. K., Sheu S-S., Gavin C. E. Mitochondrial Ca2+ transport: physiological and pathological relevance. Am. J. Physiol, 267: C313-C339, 1994.[Abstract/Free Full Text]
  16. Palmeira C. M., Wallace K. B. Benzoquinone inhibits the voltage-dependent induction of the mitochondrial permeability transition caused by redox-cycling naphthoquinones. Toxicol. Appl. Pharmacol., 143: 338-347, 1997.[Medline]
  17. Wallace K. B., Eells J. T., Madeira V. M. C., Cortopassi G., Jones D. P. Mitochondria-mediated cell injury. Fundam. Appl. Toxicol., 38: 23-37, 1997.[Medline]
  18. Bachman E., Zbinden G. Effect of doxorubicin and rubidazone on respiratory function and Ca2+ transport in rat heart mitochondria. Toxicol. Lett., 3: 29-34, 1979.
  19. Revis N. W., Marusic N. Effects of doxorubicin and its aglycone metabolite on calcium sequestration by rabbit heart, liver, and kidney mitochondria. Life Sci., 25: 1055-1064, 1979.[Medline]
  20. Sokolove P. M., Shinaberry R. G. Na+-independent release of Ca2+ from rat heart mitochondria: induction by Adriamycin aglycone. Biochem. Pharmacol., 37: 803-812, 1988.[Medline]
  21. Solem L. E., Henry T. R., Wallace K. B. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol. Appl. Pharmacol., 129: 214-222, 1994.[Medline]
  22. Solem L. E., Heller J. L., Wallace K. B. Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. J. Mol. Cell. Cardiol., 28: 1023-1032, 1996.[Medline]
  23. Solem L. E., Wallace K. B. Selective activation of the sodium-independent, cyclosporin A-sensitive calcium pore of cardiac mitochondria by doxorubicin. Toxicol. Appl. Pharmacol., 121: 50-57, 1993.[Medline]
  24. Chacon E., Acosta D. Mitochondria regulation of superoxide by Ca2+: an alternate mechanism for cardiotoxicity of doxorubicin. Toxicol. Appl. Pharmacol., 107: 117-128, 1991.[Medline]
  25. Al-Nasser I. A. In vivo prevention of Adriamycin cardiotoxicity by cyclosporin A or FK506. Toxicology, 131: 175-181, 1998.[Medline]
  26. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.[Medline]
  27. Palmeira C. M., Moreno A. J., Madeira V. M. C. Interaction of herbicides 2,4-D and dinoseb with liver mitochondrial bioenergetics. Toxicol. Appl. Pharmacol., 127: 50-57, 1994.[Medline]
  28. Erenpreisa E. A., Enkuzens A. K. Improved method of staining semithin sections with toluidine blue. Arkh. Patol., 42: 82-83, 1980.
  29. Crivellato E., Zweyer M., Basa M., Mallardi F. A ruthenium red-toluidine blue procedure for staining epoxy sections in the light microscopy. Z. Mikrosk Anat. Forsch., 104: 769-778, 1990.[Medline]
  30. Willams J. N. A method for the simultaneously quantitative estimation of cytochromes a, b, c1, and c in mitochondria. Arch. Biochem. Biophys., 107: 537-543, 1964.[Medline]
  31. Balaban R. S., Mootha V. K., Arai A. Spectroscopic determination of cytochrome c oxidase content in tissues containing myoglobin or hemoglobin. Anal. Biochem., 237: 274-278, 1996.[Medline]
  32. Broekemeier K. M., Dempsey M. E., Pfeiffer D. R. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J. Biol. Chem., 264: 7826-7830, 1989.[Abstract/Free Full Text]
  33. Custodio J. B. A., Palmeira C. M., Moreno A. J., Wallace K. B. Acrylic acid induces the glutathione-independent mitochondrial permeability transition in vitro. Toxicol. Sci., 43: 19-27, 1998.[Abstract/Free Full Text]
  34. Bernardi P. Modulation of the mitochondria cyclosporin A-sensitive permeability transition pore by the proton electrochemical gradient. J. Biol. Chem., 267: 8834-8839, 1992.[Abstract/Free Full Text]
  35. Papadopoulou L. C., Tsiftsoglou A. S. Effects of hemin on apoptosis, suppression of cytochrome c oxidase gene expression and bone marrow toxicity induced by Adriamycin. Biochem. Pharmacol., 52: 713-722, 1996.[Medline]
  36. Chernyak B. V., Bernardi P. The mitochondrial permeability transition pore is modulated by oxidative agents through both pyridine nucleotides and glutathione at two separate sites. Eur. J. Biochem., 238: 623-630, 1996.[Medline]
  37. Custodio J. B. A., Moreno A. J., Wallace K. B. Tamoxifen inhibits induction of the mitochondrial permeability transition by Ca2+ and inorganic phosphate. Toxicol. Appl. Pharmacol., 152: 10-17, 1998.[Medline]
  38. Jeyaseelan R., Poizat C., Wu H-Y., Kedes L. Molecular mechanisms of doxorubicin-induced cardiomyopathy. J. Biol. Chem., 272: 5828-5832, 1997.[Abstract/Free Full Text]
  39. Klingenberg M., Giebe K., Scherer B. The binding of atractylate and carboxy-atractylate to mitochondria. Eur. J. Biochem., 52: 351-363, 1975.[Medline]
  40. Schonfeld P. Does the function of adenine nucleotide translocase in fatty acid uncoupling depend on the type of mitochondria?. FEBS Lett., 262: 246-248, 1990.
  41. Crompton M., Virji S., Ward J. M. Cyclophilin-D binds strongly to complexes of the voltage-dependent anion channel and the adenine nucleotide translocase to form the permeability transition pore. Eur. J. Biochem., 258: 729-735, 1998.[Medline]
  42. Woodfield K., Ruck A., Brdiczka D., Halestrap A. P. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. Biochem. J., 336: 287-290, 1998.
  43. Kapelko V. I., Williams C. P., Gutstein D. E., Morgan J. P. Abnormal myocardial calcium handling in the early stage of Adriamycin cardiomyopathy. Arch. Physiol. Biochem., 104: 185-191, 1996.[Medline]
  44. Jouaville L. S., Ichas S. F., Holmuhamedov E. L., Camacho P., Lechleiter J. D. Synchronization of calcium waves by mitochondrial substrates in Xenopus laevis oocytes. Nature (Lond.), 377: 438-441, 1995.[Medline]
  45. Drummond R. M., Fay F. S. Mitochondria contribute to Ca2+ removal in smooth muscle cells. Eur. J. Physiol., 431: 473-482, 1996.[Medline]
  46. Ichas F., Jouaville L. S., Mazat J. P. Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals. Cell, 89: 1145-1153, 1995.
  47. Trollinger D. R., Cascio W. E., Lemasters J. J. Selective loading of Rhod 2 into mitochondria shows mitochondrial Ca2+ transients during the contractile cycle in adult rabbit cardiac myocytes. Biochem. Biophys. Res. Commun., 236: 738-742, 1997.[Medline]
  48. Miyamae M., Camacho S., Weiner M., Figueredo V. Attenuation of postischemic reperfusion injury is related to prevention of [Ca2+ ]m overload in rat heart. Am. J. Physiol, 271: H2145-H2153, 1996.[Abstract/Free Full Text]
  49. Olson H. M., Capen C. C. Subacute cardiotoxicity of Adriamycin in the rat: biochemical and ultrastructural investigations. Lab. Investig., 37: 386-394, 1977.[Medline]
  50. Alderton P. M., Gross J., Green M. D. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res., 52: 194-201, 1992.[Abstract/Free Full Text]
  51. Papadopoulou L. C., Theophilidis G., Thomopoulos G. N., Tsiftsoglou A. S. Structural and functional impairment of mitochondrial in Adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression. Biochem. Pharmacol., 57: 481-489, 1999.[Medline]
  52. Halestrap A. P., Davidson A. M. Inhibition of Ca2+-induced large-amplitude swelling of liver and heart mitochondria by cyclosporin is probably caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans isomerase and preventing it interacting with the adenine nucleotide translocase. Biochem. J., 268: 153-160, 1990.[Medline]
  53. Ruck A., Dolder M., Wallimann T., Brdiczka D. Reconstituted adenine nucleotide translocase forms a channel for small molecules comparable to the mitochondrial permeability transition pore. FEBS Lett., 426: 97-101, 1998.[Medline]
  54. Klingenberg M. The ADP-ATP translocation in mitochondria, a membrane potential controlled transport. J. Membr. Biol., 56: 97-105, 1980.[Medline]
  55. Palmeira C. M., Serrano J., Kuehl D. W., Wallace K. B. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim. Biophys. Acta., 1321: 101-106, 1997.[Medline]
  56. Serrano J., Palmeira C. M., Kuehl D. W., Wallace K. B. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim. Biophys. Acta., 1411: 201-205, 1999.[Medline]
  57. Billingham M. N. E., Mason J. W., Bristow M. R., Daniels J. R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep., 62: 865-872, 1978.[Medline]
  58. Bristow M. R., Mason J. W., Billingham M. E., Daniels J. R. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am. Heart J., 102: 709-718, 1981.[Medline]



This article has been cited by other articles:


Home page
 Toxicol SciHome page
Y. Will, J. A. Dykens, S. Nadanaciva, B. Hirakawa, J. Jamieson, L. D. Marroquin, J. Hynes, S. Patyna, and B. A. Jessen
Effect of the Multitargeted Tyrosine Kinase Inhibitors Imatinib, Dasatinib, Sunitinib, and Sorafenib on Mitochondrial Function in Isolated Rat Heart Mitochondria and H9c2 Cells
Toxicol. Sci., November 1, 2008; 106(1): 153 - 161.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-C. Lien, T. Noel, H. Liu, A. J. Stromberg, K.-C. Chen, and D. K. St. Clair
Phospholipase C-{delta}1 Is a Critical Target for Tumor Necrosis Factor Receptor-Mediated Protection against Adriamycin-Induced Cardiac Injury.
Cancer Res., April 15, 2006; 66(8): 4329 - 4338.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y.-C. Lien, S.-M. Lin, R. Nithipongvanitch, T. D. Oberley, T. Noel, Q. Zhao, C. Daosukho, and D. K. St. Clair
Tumor necrosis factor receptor deficiency exacerbated Adriamycin-induced cardiomyocytes apoptosis: an insight into the Fas connection.
Mol. Cancer Ther., February 1, 2006; 5(2): 261 - 269.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J. Doyle, A. I. Neugut, J. S. Jacobson, V. R. Grann, and D. L. Hershman
Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study
J. Clin. Oncol., December 1, 2005; 23(34): 8597 - 8605.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. Ascensao, J. Magalhaes, J. M. C. Soares, R. Ferreira, M. J. Neuparth, F. Marques, P. J. Oliveira, and J. A. Duarte
Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis
Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H722 - H731.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Tokarska-Schlattner, M. Zaugg, R. da Silva, E. Lucchinetti, M. C. Schaub, T. Wallimann, and U. Schlattner
Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply
Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H37 - H47.
[Abstract] [Full Text] [PDF]

Home page
 Integr Cancer TherHome page
K. A. Conklin
Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity
Integr Cancer Ther, June 1, 2005; 4(2): 110 - 130.
[Abstract] [PDF]

Home page
 JCOHome page
S. E. Lipshultz, S. R. Lipsitz, S. E. Sallan, V. M. Dalton, S. M. Mone, R. D. Gelber, and S. D. Colan
Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol., April 20, 2005; 23(12): 2629 - 2636.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
Pharmacol. Rev., June 1, 2004; 56(2): 185 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
M. E. Buyukokuroglu, S. Taysi, M. Buyukavci, and E. Bakan
Prevention of acute adriamycin cardiotoxicity by dantrolene in rats
Human and Experimental Toxicology, May 1, 2004; 23(5): 251 - 256.
[Abstract] [PDF]

Home page
 FASEB J.Home page
S. FOGLI, P. NIERI, and M. C. BRESCHI
The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage
FASEB J, April 1, 2004; 18(6): 664 - 675.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhou, S.
Right arrow Articles by Wallace, K. B.
Right arrow Search for Related Content
PubMed